CD 4802
Alternative Names: CD-4802Latest Information Update: 13 Apr 2022
Price :
$50 *
At a glance
- Originator Galderma Research & Development
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 03 Dec 2009 Galderma Research & Development complete a phase II trial in Atopic dermatitis in France (SC) (EudraCT2007-007789-39)
- 09 May 2008 Phase-II clinical trials in Atopic dermatitis in France (SC) (EudraCT2007-007789-39)